(Z)-6H-[1,3]Thiazolo[5,4-e]indole-7,8-dione 8-[N-(4-fluorophenyl)hydrazone] | 297757-09-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (Z)-6H-[1,3]Thiazolo[5,4-e]indole-7,8-dione 8-[N-(4-fluorophenyl)hydrazone]
• 英文别名: 8-[2-(4-fluorophenyl)hydrazinyl]pyrrolo[2,3-g][1,3]benzothiazol-7-one
• CAS: 297757-09-6
• 化学式: C₁₅H₉FN₄OS
• 分子量: 312.327
• InChiKey: COVGPGVAQJTNGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  94.6
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  6H-1-thia-3,6-diaza-as-indacene-7,8-dione 、 4-氟苯肼盐酸盐 生成 (Z)-6H-[1,3]Thiazolo[5,4-e]indole-7,8-dione 8-[N-(4-fluorophenyl)hydrazone]
  参考文献：
  名称：

  3-(anilinomethylene) oxindoles

  摘要：

  本发明涉及新型胺基取代的氧化吲哚化合物和组合物。这些化合物和组合物在治疗由于一般蛋白激酶激活信号通路的抑制或拮抗而缓解的疾病或病症方面具有药理学作用，特别是在涉及异常细胞增殖的病理过程，如肿瘤生长方面。具体而言，本发明涉及一系列取代氧化吲哚化合物，其表现出蛋白酪氨酸激酶和蛋白丝/苏氨酸激酶的抑制作用，并且在通过抑制与肿瘤相关的血管生成抑制肿瘤生长方面具有用处。

  公开号：

  US06350747B1

文献信息

• 3-(anilinomethylene) oxindoles
  申请人：Glaxo Wellcome Inc.

  公开号：US06350747B1

  公开（公告）日：2002-02-26

  The present invention relates generally to novel amine substituted oxindole compounds and compositions. Such compounds and compositions have utility as pharmacological agents in treating diseases or conditions alleviated by the inhibition or antagonism of protein kinase activated signalling pathways in general, and in particular in the pathological processes which involve aberrant cellular proliferation, such as tumor growth. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit protein tyrosine kinase and protein serine/threonine kinase inhibition, and which are useful in inhibiting tumor growth via inhibition of tumor-related angiogenesis.

  本发明一般涉及新型胺取代的噁二酮化合物和组合物。这些化合物和组合物作为药理学药剂在治疗由于一般蛋白激酶激活的信号通路的抑制或拮抗而减轻的疾病或症状方面具有实用性，特别是在涉及异常细胞增殖的病理过程中，如肿瘤生长。具体而言，本发明涉及一系列取代的噁二酮化合物，其表现出蛋白酪氨酸激酶和蛋白丝氨酸/苏氨酸激酶抑制作用，并且在通过抑制与肿瘤相关的血管生成抑制肿瘤生长方面是有用的。
• 3-(Anilinomethylene)oxindoles
  申请人：——

  公开号：US20020099071A1

  公开（公告）日：2002-07-25

  1 Compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, D, X, Y and Z have the meaning as defined in the claims exhibit protein tyrosine kinase and protein serin/threonine kinase inhibitory activity.

  公式（I）中的化合物，其中R1，R2，R3，R4，R5，R6，R7，R8，A，D，X，Y和Z的含义如权利要求中所定义，具有蛋白酪氨酸激酶和蛋白丝氨酸/苏氨酸激酶抑制活性。
• 3-(anilinomethylene)oxindoles
  申请人：SmithKline Beecham Corporation

  公开号：US06818632B2

  公开（公告）日：2004-11-16

  Compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, A, D, X, Y and Z have the meaning as defined in the claims, exhibit protein tyrosine kinase and protein serin/threonine kinase inhibitory activity.

  公式（I）的化合物中，其中R1，R2，R3，R4，R5，R6，R7，R8，A，D，X，Y和Z的含义如权利要求中所定义，表现出蛋白酪氨酸激酶和蛋白丝氨酸/苏氨酸激酶的抑制活性。
• 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors
  申请人：SmithKlineBeecham Corporation

  公开号：US06498176B1

  公开（公告）日：2002-12-24

  Compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, D, X, Y and Z have the meaning as defined in the claims exhibit protein tyrosine kinase and protein serin/threonine kinase inhibitory activity.

  式(I)的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、A、D、X、Y和Z的含义如权利要求所定义的那样，表现出蛋白酪氨酸激酶和蛋白丝氨酸/苏氨酸激酶抑制活性。
• Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US06369086B1

  公开（公告）日：2002-04-09

  The present invention relates generally to novel substituted oxindole compounds and compositions. Such compounds and compositions have utility as pharmacological agents in treating diseases or conditions alleviated by the inhibition or antagonism of protein kinase activated signalling pathways. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit protein tyrosine kinase and protein serine/threonine kinase inhibition, and which are useful in inhibiting tumor growth via inhibition of such kinases as well as protecting a patient undergoing chemotherapy from chemotherapy induced alopecia.

  本发明涉及新型取代的氧化吲哚化合物和组合物。这些化合物和组合物在抑制或拮抗蛋白激酶激活信号通路方面具有药理学作用，可用于治疗由此缓解的疾病或病症。特别地，本发明涉及一系列取代的氧化吲哚化合物，这些化合物表现出蛋白酪氨酸激酶和蛋白丝/苏氨酸激酶的抑制作用，并且在通过抑制这些激酶抑制肿瘤生长以及保护正在接受化疗的患者免受化疗诱发性脱发方面具有用处。